INSYS Therapeutics Reiterates Commitment to Compliant and Ethical Business Practices and Advancing Innovative Product Pipelin...
March 19 2018 - 8:00AM
INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the
development, manufacture and commercialization of pharmaceutical
cannabinoids and spray technology, today released the following
statement:
The company continues striving to take responsibility for
inappropriate actions of some former employees and has invested
significant resources over the last several years to establish an
effective compliance program and build an organizational culture of
high ethical standards. Intending to learn from past events, we
also continue working with relevant authorities to resolve issues
related to inappropriate actions taken by former employees.
Last week’s federal indictments of five New York physicians
involve allegations related to former employees. We understand that
in addition to taking responsibility for former employees’ actions,
the best ways to exhibit our desire to be a valued member of the
healthcare community are to:
- focus on the actions of current employees and reinforce an
organizational culture of high ethical standards;
- remain firmly committed to operating the business with a strong
focus on the best interests of patients; and
- continue investing in innovating new treatment options for
serious unmet patient needs.
We believe our actions over the last several years, including
our significant investment in R&D programs, illustrate our
commitment to these priorities and the company’s future.
About INSYSINSYS Therapeutics is a specialty
pharmaceutical company that develops and commercializes innovative
drugs and novel drug delivery systems of therapeutic molecules that
improve patients’ quality of life. Using proprietary spray
technology and capabilities to develop pharmaceutical cannabinoids,
INSYS is developing a pipeline of products intended to address
unmet medical needs and the clinical shortcomings of existing
commercial products. INSYS is committed to developing medications
for potentially treating addiction to opioids, opioid overdose,
epilepsy, and other disease areas with a significant unmet
need.
CONTACT: |
|
|
Corporate
Communications |
Investor
Relations |
|
|
|
Joe McGrath |
Jackie Marcus or Chris
Hodges |
|
|
|
INSYS Therapeutics |
Alpha IR Group |
|
|
|
480-500-3101 |
312-445-2870 |
|
|
|
jmcgrath@insysrx.com |
INSY@alpha-ir.com |
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Mar 2024 to Apr 2024
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Apr 2023 to Apr 2024